AffaMed is a late clinical-stage biopharmaceutical company focused on developing and commercializing pharmaceutical products that address unmet medical needs in ophthalmology. self-described.

AffaMed

AffaMed Therapeutics | 1,440 followers on LinkedIn. To Become a Leading Ophthalmology and CNS Company with Innovative Therapeutics and Solutions for China and the World. | AffaMed Therapeutics is a clinical stage therapeutic company focused on developing and commercializing transformative pharmaceutical, digital and surgical products that address critical unmet medical needs in ophthalmic, neurological and psychiatric disorders for patients in Greater China and around the world. The leadership team of AffaMed Therapeutics has gained deep industry expertise and an extensive track record in high-quality discovery, clinical development, regulatory affairs, manufacturing, commercial operations, and business development at leading multi-national pharmaceutical companies in China and globally.

Innovation & Digital Health

Lingyun (Wendy) Mao

Director of Clinical Operation

Roger Liu

Research in opthalmology

Annie Yang

Chief Regulatory Officer, Global Regulatory Science - AffaMed Therapeutics (a Biotech company)

Rose Yu

AffaMed Therapeutics

As the first NDA filing by AffaMed Therapeutics , the acceptance of our DEXTENZA NDA in Singapore represents an important milestone in our company’s journey. AffaMed is developing DEXTENZA as the first physician-administered sustained-release intracanalicular insert available to patients in the ASEAN countries and Greater China for the treatment of ocular inflammation and pain following ophthalmic surgery, and ocular itching associated with allergic conjunctivitis. For more information please visit : https://lnkd.in/gRrgAKu8 #ophthalmology #cataract #allergicconjunctivitis

Happy Chinese New Year！ AffaMed Therapeutics wishes all our friends and relationships health, wealth and happiness in the new Year of the Dragon! 新春快乐！蔼睦医疗恭祝您和您的家人龙行大运，平安喜乐！

Metric
Company Name	AffaMed
Symbol
MSH ID	COM:AFFAMED
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biopharmaceuticals
Country	CN
Stage
Employee Count
Website	affamed.com
LinkedIn	affamed-therapeutics
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

AFFA

COM:AFFAMED

AffaMed

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue